Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36935449)

  • 1. Inflammation Biomarker Response to Oral 2-Hydroxybenzylamine (2-HOBA) Acetate in Healthy Humans.
    Rathmacher JA; Fuller JC; Abumrad NN; Flynn CR
    Inflammation; 2023 Aug; 46(4):1343-1352. PubMed ID: 36935449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Hydroxybenzylamine (2-HOBA) to prevent early recurrence of atrial fibrillation after catheter ablation: protocol for a randomized controlled trial including detection of AF using a wearable device.
    O'Neill MJ; Yoneda ZT; Crawford DM; Ye F; Ao M; Pitchford LM; Rathmacher JA; Murray KT; Akers WS; Roden DM; Michaud GF; Shoemaker MB
    Trials; 2021 Aug; 22(1):576. PubMed ID: 34454591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolevuglandins as mediators of disease and the development of dicarbonyl scavengers as pharmaceutical interventions.
    Davies SS; May-Zhang LS; Boutaud O; Amarnath V; Kirabo A; Harrison DG
    Pharmacol Ther; 2020 Jan; 205():107418. PubMed ID: 31629006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolevuglandin scavenger attenuates pressure overload-induced cardiac oxidative stress, cardiac hypertrophy, heart failure and lung remodeling.
    Shang L; Weng X; Wang D; Yue W; Mernaugh R; Amarnath V; Weir EK; Dudley SC; Xu Y; Hou M; Chen Y
    Free Radic Biol Med; 2019 Sep; 141():291-298. PubMed ID: 31254620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scavenging of reactive dicarbonyls with 2-hydroxybenzylamine reduces atherosclerosis in hypercholesterolemic Ldlr
    Tao H; Huang J; Yancey PG; Yermalitsky V; Blakemore JL; Zhang Y; Ding L; Zagol-Ikapitte I; Ye F; Amarnath V; Boutaud O; Oates JA; Roberts LJ; Davies SS; Linton MF
    Nat Commun; 2020 Aug; 11(1):4084. PubMed ID: 32796843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophilic reactive aldehydes as a therapeutic target in colorectal cancer prevention and treatment.
    Gobert AP; Asim M; Smith TM; Williams KJ; Barry DP; Allaman MM; McNamara KM; Hawkins CV; Delgado AG; Zhao S; Piazuelo MB; Washington MK; Coburn LA; Rathmacher JA; Wilson KT
    Oncogene; 2023 May; 42(20):1685-1691. PubMed ID: 37037901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolevuglandins Scavenger Ameliorates Myocardial Ischemic Injury by Suppressing Oxidative Stress, Apoptosis, and Inflammation.
    Guo J; Xu F; Ji H; Jing Y; Shen L; Weng X; Hu L
    Front Cell Dev Biol; 2022; 10():836035. PubMed ID: 35356291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nutraceutical electrophile scavenger 2-hydroxybenzylamine (2-HOBA) attenuates gastric cancer development caused by Helicobacter pylori.
    Gobert AP; Asim M; Smith TM; Williams KJ; Barry DP; Allaman MM; McNamara KM; Hawkins CV; Delgado AG; Blanca Piazuelo M; Rathmacher JA; Wilson KT
    Biomed Pharmacother; 2023 Feb; 158():114092. PubMed ID: 36493697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly Reactive Isolevuglandins Promote Atrial Fibrillation Caused by Hypertension.
    Prinsen JK; Kannankeril PJ; Sidorova TN; Yermalitskaya LV; Boutaud O; Zagol-Ikapitte I; Barnett JV; Murphy MB; Subati T; Stark JM; Christopher IL; Jafarian-Kerman SR; Saleh MA; Norlander AE; Loperena R; Atkinson JB; Fogo AB; Luther JM; Amarnath V; Davies SS; Kirabo A; Madhur MS; Harrison DG; Murray KT
    JACC Basic Transl Sci; 2020 Jun; 5(6):602-615. PubMed ID: 32613146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro safety pharmacology evaluation of 2-hydroxybenzylamine acetate.
    Fuller JC; Pitchford LM; Morrison RD; Daniels JS; Flynn CR; Abumrad NN; Oates JA; Boutaud O; Rathmacher JA
    Food Chem Toxicol; 2018 Nov; 121():541-548. PubMed ID: 30253245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolevuglandins Promote Mitochondrial Dysfunction and Electrophysiologic Abnormalities in Atrial Cardiomyocytes.
    Subati T; Yang Z; Murphy MB; Stark JM; Trykall DZ; Davies SS; Barnett JV; Murray KT
    Cells; 2024 Mar; 13(6):. PubMed ID: 38534327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and 28-day repeated dose toxicity evaluations of 2-hydroxybenzylamine acetate in mice and rats.
    Pitchford LM; Smith JD; Abumrad NN; Rathmacher JA; Fuller JC
    Regul Toxicol Pharmacol; 2018 Oct; 98():190-198. PubMed ID: 30075181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subchronic (90-day) repeated dose oral toxicity study of 2-hydroxybenzylamine acetate in rabbit.
    Fuller JC; Pitchford LM; Abumrad NN; Rathmacher JA
    Regul Toxicol Pharmacol; 2018 Dec; 100():52-58. PubMed ID: 30359704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and pharmacokinetics of repeated oral doses of 2-hydroxybenzylamine acetate in healthy volunteers: a double-blind, randomized, placebo-controlled clinical trial.
    Pitchford LM; Driver PM; Fuller JC; Akers WS; Abumrad NN; Amarnath V; Milne GL; Chen SC; Ye F; Roberts LJ; Shoemaker MB; Oates JA; Rathmacher JA; Boutaud O
    BMC Pharmacol Toxicol; 2020 Jan; 21(1):3. PubMed ID: 31907026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-in-human study assessing safety, tolerability, and pharmacokinetics of 2-hydroxybenzylamine acetate, a selective dicarbonyl electrophile scavenger, in healthy volunteers.
    Pitchford LM; Rathmacher JA; Fuller JC; Daniels JS; Morrison RD; Akers WS; Abumrad NN; Amarnath V; Currey PM; Roberts LJ; Oates JA; Boutaud O
    BMC Pharmacol Toxicol; 2019 Jan; 20(1):1. PubMed ID: 30611293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dicarbonyl Electrophiles Mediate Inflammation-Induced Gastrointestinal Carcinogenesis.
    Gobert AP; Boutaud O; Asim M; Zagol-Ikapitte IA; Delgado AG; Latour YL; Finley JL; Singh K; Verriere TG; Allaman MM; Barry DP; McNamara KM; Sierra JC; Amarnath V; Tantawy MN; Bimczok D; Piazuelo MB; Washington MK; Zhao S; Coburn LA; Wilson KT
    Gastroenterology; 2021 Mar; 160(4):1256-1268.e9. PubMed ID: 33189701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subchronic (90-day) repeated dose toxicity study of 2-hydroxybenzylamine acetate in rats.
    Fuller JC; Pitchford LM; Abumrad NN; Rathmacher JA
    Regul Toxicol Pharmacol; 2018 Nov; 99():225-232. PubMed ID: 30266239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolevuglandins (isoLGs) as toxic lipid peroxidation byproducts and their pathogenetic role in human diseases.
    Aschner M; Nguyen TT; Sinitskii AI; Santamaría A; Bornhorst J; Ajsuvakova OP; da Rocha JBT; Skalny AV; Tinkov AA
    Free Radic Biol Med; 2021 Jan; 162():266-273. PubMed ID: 33099003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of reactive isolevuglandins in mitochondrial dysfunction and inflammation.
    Mayorov V; Uchakin P; Amarnath V; Panov AV; Bridges CC; Uzhachenko R; Zackert B; Moore CS; Davies S; Dikalova A; Dikalov S
    Redox Biol; 2019 Sep; 26():101300. PubMed ID: 31437812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolevuglandins disrupt PU.1-mediated C1q expression and promote autoimmunity and hypertension in systemic lupus erythematosus.
    Patrick DM; de la Visitación N; Krishnan J; Chen W; Ormseth MJ; Stein CM; Davies SS; Amarnath V; Crofford LJ; Williams JM; Zhao S; Smart CD; Dikalov S; Dikalova A; Xiao L; Van Beusecum JP; Ao M; Fogo AB; Kirabo A; Harrison DG
    JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35608913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.